Biotech innovator Bugworks Research which addresses anti-microbial resistance, secures funding from the Defense Threat Reduction Agency (DTRA) to support development of its novel broad-spectrum antibiotic BWC0977, against the most critical bacterial biothreats.
Bugworks was set up in 2014 and incubated at the Centre for Cellular And Molecular Platforms, Bangalore. The core scientific team comes with a combined experience of over 200 years in Infection Drug Discovery. Bugworks engages with multiple globally reputed partners to propel its broad spectrum assets. Amanda Horstman-Smith, Science and Technology Manager at DTRA, said, “BWC0977 with its broad spectrum efficacy against biothreat pathogens offers the potential to be a “one-stop” next-generation solution to treating biothreat infected patients. We are encouraged by the potential of Bugworks‘ assets to address critical issues in both public health and bio defense.”
“We are very delighted to collaborate with DTRA and through them get the opportunity of working with intra-government agencies within the United States Department of Defense, to advance BWC0977 as a potential single-stop solution against the most critical pathogens implicated in biothreats,” added Dr. Anand Anandkumar, CEO of Bugworks.
